Fragment-based drug discovery
π Library
π
2014
π Royal Soc Of Chemistry
π English
β¦ LIBER β¦
π
Fragment-based Drug Discovery: Lessons and Outlook
β Scribed by Daniel A. Erlanson, Wolfgang Jahnke (eds.)
- Publisher
- Wiley-VCH
- Year
- 2016
- Tongue
- English
- Leaves
- 527
- Series
- Methods and Principles in Medicinal Chemistry Volume 67
- Edition
- 1
- Category
- Library
β¬ Acquire This Volume
No coin nor oath required. For personal study only.
β¦ Synopsis
From its origins as a niche technique more than 15 years ago, fragment-based approaches have become a major tool for drug and ligand discovery, often yielding results where other methods have failed. Written by the pioneers in the field, this book provides a comprehensive overview of current methods and applications of fragment-based discovery, as well as an outlook on where the field is headed.
The first part discusses basic considerations of when to use fragment-based methods, how to select targets, and how to build libraries in the chemical fragment space. The second part describes established, novel and emerging methods for fragment screening, including empirical as well as computational approaches. Special cases of fragment-based screening, e. g. for complex target systems and for covalent inhibitors are also discussed. The third part presents several case studies from recent and on-going drug discovery projects for a variety of target classes, from kinases and phosphatases to targeting protein-protein interaction and epigenetic targets.
β¦ Subjects
Chemistry;Pharmacology;Pharmacy;Pharmacology;Pharmacy;Allied Health Services;Medicine & Health Sciences;New, Used & Rental Textbooks;Specialty Boutique;Pharmacology;Basic Sciences;Medicine;Medicine & Health Sciences;New, Used & Rental Textbooks;Specialty Boutique
π SIMILAR VOLUMES
Fragment-Based Drug Discovery
β Steven Howard, Chris Abell (eds.)
π Library
π
2015
π Royal Society of Chemistry
π English
<P>Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is
Fragment-Based Drug Discovery
β Steven Howard, Chris Abell (eds.)
π Library
π
2015
π Royal Society of Chemistry
π English
<P>Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is
Fragment-Based Drug Discovery and X-Ray
β Daniel A. Erlanson (auth.), Thomas G. Davies, Marko HyvΓΆnen (eds.)
π Library
π
2012
π Springer-Verlag Berlin Heidelberg
π English
<p><p>Introduction to Fragment-Based Drug Discovery, by Daniel A. Erlanson </p><p>Fragment Screening Using X-Ray Crystallography, by Thomas G. Davies and Ian J. Tickle</p><p>Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening, by Stephen Roughley, Lisa Wright, Paul Brough, Andrew Massey a
Fragment-Based Drug Discovery and X-Ray
β Daniel A. Erlanson (auth.), Thomas G. Davies, Marko HyvΓΆnen (eds.)
π Library
π
2012
π Springer-Verlag Berlin Heidelberg
π English
<p><p>Introduction to Fragment-Based Drug Discovery, by Daniel A. Erlanson </p><p>Fragment Screening Using X-Ray Crystallography, by Thomas G. Davies and Ian J. Tickle</p><p>Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening, by Stephen Roughley, Lisa Wright, Paul Brough, Andrew Massey a
Fragment-Based Drug Discovery and X-Ray
β Daniel A. Erlanson (auth.), Thomas G. Davies, Marko HyvΓΆnen (eds.)
π Library
π
2012
π Springer-Verlag Berlin Heidelberg
π English
<p><p>Introduction to Fragment-Based Drug Discovery, by Daniel A. Erlanson </p><p>Fragment Screening Using X-Ray Crystallography, by Thomas G. Davies and Ian J. Tickle</p><p>Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening, by Stephen Roughley, Lisa Wright, Paul Brough, Andrew Massey a